Drug Profile
Adavosertib - AstraZeneca
Alternative Names: AZD-1775; L001739996-008U; MK-1775; MK-1775 hemihydrateLatest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer AstraZeneca; Canadian Cancer Trials Group; Cancer Research UK; Dana-Farber Cancer Institute; Merck & Co; National Cancer Institute (USA); Samsung Medical Center; University of Birmingham; University of Texas M. D. Anderson Cancer Center; University of Washington
- Class Aniline compounds; Antineoplastics; Piperazines; Pyrazoles; Pyridines; Pyrimidinones; Small molecules
- Mechanism of Action WEE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Triple negative breast cancer
- Phase I Haematological disorders; Head and neck cancer; Uterine cancer
- Preclinical Diffuse large B cell lymphoma; Gastric cancer
- No development reported Colorectal cancer; Glioblastoma; Vulvovaginal cancer
- Discontinued Cervical cancer
Most Recent Events
- 28 Nov 2023 H. Lee Moffitt Cancer Center and Research Institute complete a phase II trial in Non-small cell lung cancer (Combination therapy, Late stage disease, Metastatic disease) in USA (NCT02513563)
- 02 Jun 2023 Efficacy and adverse events data from a phase II trial in Solid tumours presented at the at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 30 Apr 2023 The Netherlands Cancer Institute completes phase-II trial in Ovarian cancer (Combination therapy, Second-line therapy or greater) in the Netherlands (PO) (NCT01164995)